Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 1

Conditions

Neoplasms 5Pain 2Constipation 2Cancer Pain 2Bronchiolitis Obliterans Syndrome 2Osteoarthritis 1Lymphoma, Follicular 1Intestinal Obstruction 1Back Pain 1

Interventions

ibrutinib 9tofacitinib 7Imatinib Mesylate 5ruxolitinib 4ofatumumab 4Rituximab 4Dasatinib 4nilotinib 3fludarabine 3bosutinib 3asciminib 3Sirolimus 3Mycophenolic Acid 3Cyclophosphamide 3obinutuzumab 2Pentostatin 2Oxycodone 2Naloxone 2KW-2478 2Filgrastim 2Alemtuzumab 2ziconotide 1sodium luminolate 1posaconazole 1ponatinib 1pegfilgrastim 1oblimersen 1montelukast 1mocetinostat 1milatuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Bronchiolitis Obliterans Syndrome × Naloxone × Clear all
NCT00513656 2018-10-23

A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain

Mundipharma Research GmbH & Co KG

Phase 2 Completed
230 enrolled
Other

Bronchiolitis Obliterans Syndrome, Constipation, Neoplasms, Pain

NCT02321397 2016-11-04

To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain

Mundipharma Research GmbH & Co KG

Phase 2/3 Completed
155 enrolled

Bronchiolitis Obliterans Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡